European Journal of Cancer
Volume 46, Issue 1 , Pages 84-94 , January 2010

Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: Results of a randomised trial (GABG-IV E-93) – The German Adjuvant Breast Cancer Group

  • Wolfgang Eiermann

      Affiliations

    • Frauenklinik vom Roten Kreuz, Taxistraße 3, 80637 München, Germany
    • Corresponding Author InformationCorresponding author: Tel.: +49 89 15706 620x621; fax: +49 89 15706 623.
    • ,
  • Erika Graf

      Affiliations

    • Medizinische Biometrie und Statistik, Universitätsklinikum Freiburg, Stefan-Meier-Straße 26, 79104 Freiburg, Germany
    • ,
  • Beyhan Ataseven

      Affiliations

    • Frauenklinik vom Roten Kreuz, Taxistraße 3, 80637 München, Germany
    • ,
  • Bettina Conrad

      Affiliations

    • Brustzentrum, Elisabeth-Krankenhaus Kassel, Weinbergstraße 7, 34117 Kassel, Germany
    • ,
  • Jörn Hilfrich

      Affiliations

    • Henriettenstiftung, Schwemannstraße 17, 30559 Hannover, Germany
    • ,
  • Heidi Massinger-Biebl

      Affiliations

    • Gemeinschaftspraxis, Marktplatz/Weißbräugasse 2a, 94065 Waldkirchen, Germany
    • ,
  • Sabine Vescia

      Affiliations

    • Stadtkrankenhaus Hanau, Leimenstr. 20, 63450 Hanau, Germany
    • ,
  • Sibylle Loibl

      Affiliations

    • German Breast Group, GBG Forschungs GmbH, Schleussnerstraße 42, 63263 Neu-Isenburg, Germany
    • ,
  • Gunter von Minckwitz

      Affiliations

    • German Breast Group, GBG Forschungs GmbH, Schleussnerstraße 42, 63263 Neu-Isenburg, Germany
    • Klinik für Gynäkologie und Geburtshilfe, J.W. Goethe Universität, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany
    • ,
  • Martin Schumacher

      Affiliations

    • Medizinische Biometrie und Statistik, Universitätsklinikum Freiburg, Stefan-Meier-Straße 26, 79104 Freiburg, Germany
    • ,
  • Manfred Kaufmann

      Affiliations

    • Klinik für Gynäkologie und Geburtshilfe, J.W. Goethe Universität, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany
    • ,
  • for the German Adjuvant Breast Cancer Group

Received 23 June 2009 ,Revised 1 September 2009 ,Accepted 1 October 2009.

References 

  1. Buzzoni R, Bonadonna G, Valagussa P, et al. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol. 1991;9:2134–2140
  2. Von Minckwitz G, Graf E, Geberth M, et al. CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93). Eur J Cancer. 2006;42:1780–1788
  3. Kaufmann M, Graf E, Jonat W, et al. A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer – GABG-IV B-93. Eur J Cancer. 2007;43:2351–2358
  4. Kaufmann M, Graf E, Jonat W, et al. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93) – the German Adjuvant Breast Cancer Group. J Clin Oncol. 2005;23:7842–7848
  5. The French Epirubicin Study Group. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin. J Clin Oncol. 1988;6:679–688
  6. Schumacher M, Bastert G, Bojar H, et al. Randomized 2×2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. J Clin Oncol. 1994;12:2086–2093
  7. Carmo-Pereira J, Costa FO, Miles DW, et al. High-dose epirubicin as primary chemotherapy in advanced breast carcinoma: a phase II study. Cancer Chemother Pharmacol. 1991;27:394–396
  8. Zander AR, Kröger N, Schmoor C, et al. High-dose chemotherapy with autologous haematopoietic stem-cell support vs. standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: First result of a randomised trial. J Clin Oncol. 2004;22:2273–2283
  9. Eiermann W, Graf E, Raab G, et al. High-dose epirubicin vs. standard-dose epirubicin–cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: first results of a randomised trial of the German Adjuvant Breast Cancer Group (GABG). Proc ASCO. 2001;20:127
  10. Haybittle JL, Blamey RW, Elston CW, et al. A prognostic index in primary breast cancer. Brit J Cancer. 1982;45:361–366
  11. Lee AH, Ellis IO. The Nottingham Prognostic Index for invasive carcinoma of the breast. Pathol Oncol Res. 2008;14:113–115
  12. Schmoor C, Olschewski M, Sauerbrei W, Schumacher M. Long-term follow-up of patients in four prospective studies of the German Breast Cancer Study Group (GBSG): a summary of key results. Onkologie. 2002;25:143–150
  13. Clark TG, Altman DG, De Stavola BL. Quantification of the completeness of follow-up. Lancet. 2002;359:1309–1310
  14. Berteheau P, Turpin E, Rickman DS, et al. Exquisite sensitivity of TP53 mutant, basal breast cancers to a dose-dense epirubicin–cyclophosphamide regimen. PLOS Med. 2007;4:e90
  15. Colleoni M, Sun Z, Martinelli G, et al. The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Ann Oncol. 2009;20:1344–1351
  16. Tallman MS, Gray R, Robert NJ, et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. New Engl J Med. 2003;349:17–26
  17. Hanrahan EO, Broglio K, Frye D, et al. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years. Cancer. 2006;106(June):2327–2336
  18. International Breast Cancer Study Group. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95. J Clin Oncol. 2006;24:370–378
  19. Untch M, Thomssen C, Steffen, K, et al. Five year results of a randomised multicenter dose intense (DI-EC) study with epirubicin (E) and cyclophosphamide (C) in high risk breast cancer patients – a treatment of short duration with comparable efficacy to conventional chemotherapy. Breast Cancer Res Treat 2002;76:S128 [Abstract 641].
  20. Untch M, Möbus V, Kuhn W, et al. Intensive dose-dense chemotherapy compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol. 2009;27:1–9
  21. Farquhar C, Marjoribanks J, Basser R, Lethaby A. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer. Cochrane Database Syst Rev 2005:CD003139.
  22. Roche H, Viens P, Biron P, et al. High dose chemotherapy for breast cancer: the French PEGASE experience. Cancer Contr. 2003;10:42–47
  23. de Azambuja E, Paesmans M, Beauduin M, et al. Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study. J Clin Oncol. 2009;27:720–725
  24. Rodenhuis S, Bontenbal M, Beex LVAM, et al. High-dose chemotherapy with hematopoetic stem-cell rescue for high-risk breast cancer. New Engl J Med. 2003;349:7–16
  25. Schrama JG, Faneyte IF, Schornagel JH, et al. Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years follow-up. Ann Oncol. 2002;13:689–698
  26. von Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol. 2005;23:2676–2685
  27. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24:2019–2027
  28. Bonadonna G, Moliterni A, Zambetti M, et al. 30 Years’ follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ. 2005;330(7485):217
  29. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21:1431–1439
  30. Möbus VJ, Lück HJ, Thomssen C, et al. Dose-dense sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) in comparison to conventional dosed chemotherapy in high-risk breast cancer patients (⩾4+LN). Mature results of an AGO-trial. San Antonio Breast Cancer Symposium; 2006 [Abstract 43].

☆ This report presents the final analysis of trial GABG-IV E-93. Preliminary results were reported at the ASCO Annual Meeting in 2001.

PII: S0959-8049(09)00726-6

doi: 10.1016/j.ejca.2009.10.001

European Journal of Cancer
Volume 46, Issue 1 , Pages 84-94 , January 2010

Article Tools

* Image Usage & Resolution